Xention
2002
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
2ndary - Private
LATEST DEAL TYPE
11
INVESTORS
Description
Developer of novel therapies created for the treatment of atrial fibrillation. The company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need. It's ion channel-modulating drugs are used for the treatment of atrial fibrillation, overactive bladder, pain and autoimmune diseases.
Website
Formerly Known As
Xention Discovery
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Primary Office
- 38 High Street
- Newmarket
- Suffolk CB8 8LB
- England, United Kingdom
+44 01223 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Xention’s full profile, request a free trial.
Xention Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 000.00 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 00.000 | 000.00 | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series D) | 23-Nov-2010 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 5. Early Stage VC | 25-Jun-2010 | 000.00 | Completed | Generating Revenue | ||
| 4. Later Stage VC | 31-Mar-2008 | 000.00 | Completed | Generating Revenue | ||
| 3. Early Stage VC | 18-Jul-2005 | 000.00 | 000.00 | Completed | Startup | |
| 2. Early Stage VC | 16-Sep-2003 | $6.34M | $12.8M | Completed | Startup | |
| 1. Early Stage VC | 01-Aug-2002 | $6.5M | $6.5M | Completed | Startup |
Xention Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | 0 | 000.00 | 00000000000 | 000.00 |
| 00000 000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 0000 | 000000&0 | 0000 |
| 0000000000 | Formerly VC-backed | Cambridge, MA | 00 | 0000 | 000000&0 | 0000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 00 | 0000 | 000000&0 | 0000 |
| 000 000000000 | Corporation | Gainesville, FL | 0 | 00.000 | 000000000000 | 00.000 |
Xention Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Seroba Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Foresight Group | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Gresham House Strategic Public Equity | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| ABN AMRO AAH.AS | Investment Bank | Minority | 000 0000 | 000000 0 | ||
| Omnes Capital | PE/Buyout | Minority | 000 0000 | 000000 0 |
Xention Executive Team (5)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Timothy Brears Ph.D | Chief Executive Officer & Board Member | ||
| Keith McCullagh Ph.D | Board Member & Executive Chairman |
3 Former Executives
You’re viewing 2 of 5 executives. Get the full list »Xention Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alan O'Connell Ph.D | Seroba Life Sciences | Board Member | 000 0000 | |
| Graham Fagg Ph.D | Self | Board Member | 000 0000 | |
| Jonathan Gee Ph.D | Gresham House Strategic Public Equity | Board Member | 000 0000 | |
| Keith McCullagh Ph.D | Xention | Board Member & Executive Chairman | 000 0000 | |
| Kenneth Cunningham | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 13 board members. Get the full list »